A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01899079

Enrollment

217

Registered

2013-07-15

Start date

2013-06-30

Completion date

2014-07-31

Last updated

2015-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast Cancer, Prosigna, FFPE, node negative, estrogen receptor positive, HER2 negative

Brief summary

The primary objective of this study is to assess the extent to which the Prosigna™ Breast Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and actual treatments received for patients with early-stage breast cancer.

Detailed description

Changes in treatment recommendations will include (1) hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of chemotherapy if chemotherapy was recommended before and after the Prosigna test.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0) 1. Estrogen receptor status will be evaluated by Immunohistochemistry (IHC)and more than 1% of stained tumor cells will be considered positive. 2. HER2 status will be evaluated by (IHC; 0 or 1+, or 2+ will be considered negative) and by in-situ fluorescence hybridization. * Postmenopausal females, which is defined as: 1. Natural Amenorrhea \> 12 months, regardless of age 2. Bilateral oophorectomy, regardless of age (the oophorectomy must have been carried out at least 4 weeks before entering the study) 3. Radiological castration with amenorrhea \> 3 months, regardless of age 4. Hysterectomy and postmenopausal blood levels * Able to give consent * Eligible for treatment of breast cancer with adjuvant chemotherapy * ECOG performance status of 0 or 1

Exclusion criteria

* Tumor size T3-T4 * Non-invasive breast cancer (e.g., Paget's disease, DCIS) * Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+) * Tumors that are estrogen-receptor negative or HER2 positive * Have metastatic disease * Unable to give informed consent * Unable to complete patient reported outcome surveys * Have contraindications for adjuvant chemotherapy * Age, performance status, significant comorbidities * ECOG performance status \> 1

Design outcomes

Primary

Measure	Time frame
The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result	6 months

Countries

Spain

Outcome results